4.8 Article

Dual-Functionalized Janus Mesoporous Silica Nanoparticles with Active Targeting and Charge Reversal for Synergistic Tumor-Targeting Therapy

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 11, Issue 47, Pages 44582-44592

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.9b15434

Keywords

Janus nanoparticles; mesoporous silica nanoparticles; charge reversal; targeted drug delivery; doxorubicin

Funding

  1. Natural Science Foundation of Liaoning Province [20170540155, 20170540148, 20170540184]
  2. National Natural Science Foundation of China [31670767, 81603049]
  3. Fundamental Research Funds for the Central Universities of China [DUT15RC(3)042, DUT17RC(4)31, DUT17ZD214, DUT17JC36, DUT17RC(4)27]

Ask authors/readers for more resources

Janus nanoparticles with an anisotropic feature concentrated multiple properties on a single carrier, providing synergistic effects. In this study, dual-functionalized Janus nanoparticles (HA-JMSN/DOX-DMMA) were constructed with a tumor-targeting ligand (hyaluronic acid, HA) modified on the one side and a charge reversal group (2,3-dimethylmaleic anhydride, DMMA) on the other side. The drug release of HA-JMSN/DOX-DMMA was positively correlated with the acidity of the environment. The cytotoxicity and cell uptake of HA-JMSN/DOX-DMMA were superior to the isotropous nanoparticles. The endocytosis pathway of HA-JMSN/DOX-DMMA involved the clathrin-mediated endocytosis (HA) and the micropinocytosis (DMMA) at the same time, which indicated that they both participated in the interaction between nanoparticles and tumor cells. After being injected intravenously in mice, the distribution of HA-JMSN/DOX-DMMA in tumor was enhanced significantly. The antitumor therapy study in vivo showed that HA-JMSN/DOX-DMMA inhibited tumor growth and improved the survival rate of tumor-bearing mice effectively. In general, HA-JMSN/DOX-DMMA could take the synergistic effect of active targeting and charge reversal to deliver drug in tumor cells and kill them efficiently, which was a promising antitumor nanodrug.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available